Annexin-Ⅱ及VEGF-C在甲状腺乳头状癌中的表达及其意义被引量：4

The Expression and Significance of Annexin-Ⅱ and VEGF-C in Papillary Thyroid Carcinoma

下载PDF

导出

摘要目的观察Annexin-Ⅱ及VEGF-C在甲状腺乳头状癌中的表达及其临床意义。方法使用免疫组化的方法检测44例甲状腺乳头状癌、16例甲状腺腺瘤、20例结节性甲状腺肿及10例正常甲状腺组织中Annexin-Ⅱ及VEGF-C的表达情况及与临床病理的关系。结果 Annexin-Ⅱ及VEGF-C在甲状腺乳头状癌中的阳性表达率明显高于甲状腺腺瘤、结节性甲状腺肿及正常甲状腺组织;Annexin-Ⅱ及VEGF-C的表达与肿瘤大小及淋巴结转移有关,差异有统计学意义。结论 Annexin-Ⅱ及VEGF-C的表达与甲状腺乳头状癌的发生有密切关系,且与甲状腺乳头状癌的发展及淋巴结转移有一定关系。 Objective To study the expression of Annexin- Ⅱ and VEGF-C in papillary thyroid carcinoma. Methods The expression of Annexin-Ⅱ and VEGF-C were detected, in 44 cases of papillary thyroid carcinoma, 16 cases of thyroid adenoma, 20 cases of nodular goiter and 10 cases of normal thyroid tissue, using immunohistochemical method. Results The expression levels of Annexin- Ⅱ and VEGF-C in papillary carcinoma were significantly higher than that in thyroid adenoma, nodular goiter and normal thyroid tissue. The expression levels of Annexin-Ⅱ and VEGF-C were correlated with tumor size and lymph node metastasis, and the difference was statistically significant. Conclusion The Annexin-Ⅱand VEGF-C areintimately related to the occurrence of papillary carcinoma, and also related to the development of papillary carcinoma and lymph node metastasis.

作者曹龄之杨凡慧温琥玲谢建平李素平

机构地区川北医学院附属医院核医学科

出处《标记免疫分析与临床》 CAS 2017年第5期542-544,共3页 Labeled Immunoassays and Clinical Medicine

关键词甲状腺乳头状癌 Annexin—Ⅱ VEGF-C Papillary thyroid carcinoma Annexin- Ⅱ VEGF-C

分类号 R736.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1黄蕤,李林.分化型甲状腺癌的放射性碘-131治疗[J].中国普外基础与临床杂志,2012,19(8):814-817. 被引量：18
2李庆昌,董昕,顾伟,邱雪杉,王恩华.Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer[J].Chinese Medical Journal,2003(5):727-730. 被引量：48

二级参考文献15

1何英,潘明志,戚忠智.^(131)I-SPECT/CT融合显像诊断分化型甲状腺癌转移灶的临床价值[J].四川大学学报（医学版）,2010,41(4):734-736. 被引量：6
2Schlumberger MJ. Papillary and follicular thyroid carcinoma [J]. N Engl J Med, 1998, 338(5): 297-306.
3Siegel R, Ward E, Brawley O. et al. Cancer statistics, 2011 : the impact of eliminating socioeconomic and racial disparities on premature cancer deaths [J]. CA Cancer J Clin, 2011, 61(4):212-236.
4Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007 [J]. Asia Pac J Public Health, 2012, Mar 16. [Epub ahead of print].
5Beeker DV, Clark TS. Radioiodine and thyroid disease: the beginning [J]. Semin Nucl Med, 1996, 26(3): 155-164.
6Cooper DS, Doherty GM, Haugen BR, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J]. Thyroid, 2009, 19(11): 1167-1214.
7Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hiirthle-cell follicular thyroid carcinoma [J]. Ann intern Med, 1998, 129(8): 62-627.
8Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma [J]. Cancer, 1998, 82(2): 375-388.
9Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer [J]. J Clin Endocrinol Metab, 2001, 86(4): 1447-1463.
10Wartofsky L, Sherman Si, Gopal J, et al. The use of radioactive iodine in patients with papillary and follicular thyroid cancer [J]. J Clin Endocrinol Metab, 1998, 83(12): 4195-4203.